Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (17 ops.)
Latest filing published 21 Sept 2026 for Enliven Therapeutics, Inc., €11k. Read the official filing
Filing timeline
BuySaleHelen Louise Collins
Insider track record
Disclosed buys
0
Disclosed sells
17
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Helen Louise Collins: trading record in brief
Helen Louise Collins discloses dealings in Enliven Therapeutics, Inc. to SEC (Form 4). The record holds 29 filings, for trades running from 11 April 2024 to 17 September 2026.
Sales make up the whole of the open-market record (17 sales, €928k). The amount is not disclosed for 3 filings. Besides market trades, the filings include 1 share grant and 11 option exercises. Since January 2026: no purchases and 16 sales on the market.
The newest entry dates from 21 September 2026: an option exercise of €11k, in Enliven Therapeutics, Inc. Typically, a trade is published a median of 4 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Helen Louise Collins
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations29 total
5,000 shares@ US$2.48Common StockSEC:0001701247-26-000013:0
2,916 shares@ US$50.0312Common StockSEC:0001701247-26-000013:1
1,844 shares@ US$50.7089Common StockSEC:0001701247-26-000013:2
240 shares@ US$51.482Common StockSEC:0001701247-26-000013:3
5,000 shares@ US$2.480.0003% mcap0.6% of flowCommon StockSEC:0001701247-26-000012:0
3,900 shares@ US$58.37170.0053% mcap11.5% of flowCommon StockSEC:0001701247-26-000012:1
1,100 shares@ US$59.34650.0015% mcap3.3% of flowCommon StockSEC:0001701247-26-000012:2
63 shares@ US$53.92080.0001% mcap0.2% of flowCommon StockSEC:0001701247-26-000011:5
2,063 shares@ US$52.39210.0029% mcap6.5% of flowCommon StockSEC:0001701247-26-000011:3
5,000 shares@ US$2.480.0003% mcap0.7% of flowCommon StockSEC:0001701247-26-000011:0
231 shares@ US$50.05420.0003% mcap0.7% of flowCommon StockSEC:0001701247-26-000011:1
459 shares@ US$51.54660.0006% mcap1.4% of flowCommon StockSEC:0001701247-26-000011:2
2,184 shares@ US$53.41990.0031% mcap7.1% of flowCommon StockSEC:0001701247-26-000011:4
2,599 sharesCommon StockSEC:0001701247-26-000010:2
5,000 sharesCommon StockSEC:0001701247-26-000010:0
1,268 sharesCommon StockSEC:0001701247-26-000010:1
1,133 sharesCommon StockSEC:0001701247-26-000010:3
140 shares@ US$45.81070.0001% mcap1.9% of flowCommon StockSEC:0001701247-26-000006:1
2,419 shares@ US$47.38960.0026% mcap34.3% of flowCommon StockSEC:0001701247-26-000006:2
2,441 shares@ US$48.05550.0027% mcap35.1% of flowCommon StockSEC:0001701247-26-000006:3
5,000 shares@ US$2.480.0003% mcap3.7% of flowCommon StockSEC:0001701247-26-000006:0
40,000 shares@ US$2.4823.2% of flowCommon StockSEC:0001701247-26-000005:0
5,000 shares@ US$2.482.8% of flowCommon StockSEC:0001701247-26-000004:0
29,871 shares@ US$2.4811.9% of flowCommon StockSEC:0001701247-26-000003:0
45,000 shares@ US$2.4817.5% of flowCommon StockSEC:0001701247-26-000002:0
25 of 29 declarations
